CEO Leon Moulder Jr. Discloses 5.09% Beneficial Ownership, Confirming Recent Share Purchases

summarizeSummary

Zenas BioPharma's CEO, Leon O. Moulder Jr., along with affiliated entities, filed a Schedule 13D disclosing a 5.09% beneficial ownership stake, which includes recent open-market purchases.

check_boxKey Events

• CEO's Beneficial Ownership

  Leon O. Moulder Jr., through direct and affiliated holdings, beneficially owns 3,220,880 shares, representing 5.09% of the company's common stock.

• Recent Share Purchases Confirmed

  The filing confirms the Reporting Persons purchased an aggregate of 271,000 shares in open-market transactions between January 7 and April 29, 2026, at prices ranging from $15.82 to $19.58 per share.

• Reinforces Prior Disclosure

  This 13D provides a comprehensive overview of the CEO's total beneficial ownership, building on the recent Form 4 filing that reported a significant purchase by Mr. Moulder on April 29, 2026.

auto_awesomeAnalysis

This Schedule 13D filing confirms that CEO and Chairman Leon O. Moulder Jr., through his direct holdings and affiliated entities (Tellus BioVentures, LLC and a revocable trust), beneficially owns 5.09% of Zenas BioPharma's common stock. The filing details recent open-market purchases of 271,000 shares between January 7 and April 29, 2026, reinforcing the CEO's confidence in the company. This follows a previous Form 4 filing on April 29, 2026, which reported a specific purchase by Mr. Moulder. The aggregation of these holdings and the establishment of the 5% beneficial ownership threshold provide a comprehensive view of the CEO's significant and growing stake, which can be interpreted as a strong positive signal for investors, especially given the company's recent positive Phase 3 results and ongoing efforts to address a going concern warning.